

Wassim H Fares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2137396/publications.pdf>

Version: 2024-02-01

57
papers

816
citations

623734

14
h-index

552781

26
g-index

57
all docs

57
docs citations

57
times ranked

1395
citing authors

#	ARTICLE	IF	CITATIONS
1	PECAM-1 is Associated With Outcomes and Response to Treatment in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2020, 127, 198-199.	1.6	1
2	Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 77.	2.4	6
3	Hospitalizations with hereditary hemorrhagic telangiectasia and pulmonary hypertension in the United States from 2000 to 2014. <i>Respiratory Medicine</i> , 2019, 147, 26-30.	2.9	6
4	S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. <i>Respirology</i> , 2018, 23, 771-779.	2.3	18
5	Is hyponatremia associated with mortality in pulmonary arterial hypertension?. <i>Pulmonary Circulation</i> , 2018, 8, 1-7.	1.7	4
6	Pulmonary hypertension in patients with interstitial lung disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 38-46.	2.6	21
7	Staged Endovascular Intervention of Bilateral Pulmonary Artery Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 607-609.	2.9	0
8	Risk factors for presence and severity of pulmonary embolism in patients with deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2018, 6, 7-12.	1.6	14
9	Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review. <i>Respiratory Medicine</i> , 2018, 134, 42-46.	2.9	18
10	Reply. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2018, 6, 560-561.	1.6	0
11	Endovascular Treatment of a Large Iliac Vein Aneurysm and High-Flow Arteriovenous Fistula. <i>Annals of Vascular Surgery</i> , 2018, 53, 266.e5-266.e7.	0.9	9
12	Chronic Right Heart Failure. <i>Heart Failure Clinics</i> , 2018, 14, 413-423.	2.1	5
13	Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 314, L782-L796.	2.9	71
14	Venous Thromboembolism: An Evolving Entity. <i>Clinics in Chest Medicine</i> , 2018, 39, xv-xvi.	2.1	0
15	Hypercoagulability in Pulmonary Hypertension. <i>Clinics in Chest Medicine</i> , 2018, 39, 595-603.	2.1	18
16	Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1353-1356.	5.6	14
17	A systematic review of transition studies of pulmonary arterial hypertension specific medications. <i>Pulmonary Circulation</i> , 2017, 7, 326-338.	1.7	22
18	Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?. <i>Pulmonary Circulation</i> , 2017, 7, 727-729.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Finally, Progress in Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 56, 421-422.	2.9	0
20	Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 730-733.	1.7	10
21	Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 186-199.	1.7	57
22	Characteristics of provoked deep venous thrombosis in a tertiary care center. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 477-484.	1.6	2
23	A 49-Year-Old Man with Subacute Respiratory Failure and Interstitial Lung Opacities. <i>American Journal of Case Reports</i> , 2017, 18, 941-944.	0.8	7
24	Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1251-1261.	5.6	51
25	Chronic Thromboembolic Pulmonary Hypertension: A Worldwide View of How Far We Have Come. <i>Lung</i> , 2016, 194, 483-485.	3.3	2
26	Plexin C1 deficiency permits synaptotagmin 7-mediated macrophage migration and enhances mammalian lung fibrosis. <i>FASEB Journal</i> , 2016, 30, 4056-4070.	0.5	50
27	Reply: Oral Treprostinil Combination Trials Post Hoc Secondary Analyses: A Step toward Verifying Its Efficacy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1437-1438.	5.6	2
28	Pushing the Envelope on the Indications and Doses of Pulmonary Arterial Hypertension Medications. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 319-321.	1.9	1
29	Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 760-767.	0.6	22
30	Review of the Ongoing Story of Appetite Suppressants, Serotonin Pathway, and Pulmonary Vascular Disease. <i>American Journal of Cardiology</i> , 2016, 117, 1691-1696.	1.6	11
31	Novel Mechanisms of Disease: Network Biology and MicroRNA Signaling in Pulmonary Hypertension. , 2016, , 123-133.		2
32	Pulmonary hypertension: diagnostic and therapeutic challenges. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1221.	2.0	32
33	Lupus-Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition. <i>Case Reports in Medicine</i> , 2015, 2015, 1-5.	0.7	11
34	Controversies and Evolving Concepts in Critical Care. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 807-808.	2.1	0
35	The Assessment of the Right Heart Failure Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 934-942.	2.1	3
36	Pulmonary Hypertension in Obstructive Sleep Apnea: Is it Clinically Significant? a Critical Analysis of the Association and Pathophysiology. <i>Pulmonary Circulation</i> , 2015, 5, 220-227.	1.7	85

#	ARTICLE	IF	CITATIONS
37	Orenitram . . . Not Verified. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 713-714.	5.6	7
38	Management of Right Heart Failure in the Intensive Care Unit. Clinics in Chest Medicine, 2015, 36, 511-520.	2.1	20
39	Macitentan for the treatment of pulmonary arterial hypertension. Vascular Health and Risk Management, 2014, 10, 665.	2.3	17
40	The Other Vascular Beds in Pulmonary Arterial Hypertension. Surrogates or Associated?. Annals of the American Thoracic Society, 2014, 11, 596-597.	3.2	2
41	Unresolved pulmonary embolism leading to a diagnosis of pulmonary artery sarcoma. Heart and Lung: Journal of Acute and Critical Care, 2014, 43, 574-576.	1.6	9
42	The "availability" bias: underappreciated but with major potential implications. Critical Care, 2014, 18, 118.	5.8	6
43	The relationship between positive end-expiratory pressure and cardiac index in patients with acute respiratory distress syndrome. Journal of Critical Care, 2013, 28, 992-997.	2.2	4
44	Standard Nonspecific Therapies in the Management of Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2013, 34, 799-810.	2.1	13
45	Amiodarone and the risk of cancer: A nationwide population-based study. Cancer, 2013, 119, 4051-4051.	4.1	2
46	Not All Catheter-Days Are Equal. Critical Care Medicine, 2013, 41, e14.	0.9	1
47	Targeted approaches to the treatment of pulmonary hypertension. Therapeutic Advances in Respiratory Disease, 2012, 6, 147-159.	2.6	12
48	Safety and Feasibility of Obtaining Wedged Pulmonary Artery Samples and Differential Distribution of Biomarkers in Pulmonary Hypertension. Pulmonary Circulation, 2012, 2, 477-482.	1.7	7
49	Thermodilution and Fick Cardiac Outputs Differ: Impact on Pulmonary Hypertension Evaluation. Canadian Respiratory Journal, 2012, 19, 261-266.	1.6	41
50	Persistent left superior vena cava identified during central line placement: A case report. Respiratory Medicine CME, 2011, 4, 141-143.	0.1	13
51	Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment, and Dana Point World Symposium Highlights. Current Respiratory Medicine Reviews, 2011, 7, 279-288.	0.2	1
52	Management of acute decompensated heart failure in an evidence-based era: What is the evidence behind the current standard of care?. Heart and Lung: Journal of Acute and Critical Care, 2008, 37, 173-178.	1.6	6
53	Should beta-blockers be discontinued when a patient is admitted to the hospital with acutely decompensated heart failure?. Cleveland Clinic Journal of Medicine, 2006, 73, 557-559.	1.3	2
54	Is postoperative atrial fibrillation in patients undergoing noncardiothoracic surgery an important problem? IMPACT consults. Proceedings of the 2nd Annual Cleveland Clinic Perioperative Medicine Summit.. Cleveland Clinic Journal of Medicine, 2006, 73, S20-S20.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. American Journal of Cardiology, 2004, 93, 1533-1535.	1.6	50
56	Superior vena cava syndrome secondary to saphenous venous graft aneurysm with right atrial fistula. Catheterization and Cardiovascular Interventions, 2003, 60, 45-47.	1.7	14
57	Inhibition of restenosis by hyperbaric oxygen. Cardiovascular Radiation Medicine, 2002, 3, 124-126.	0.6	10